Cover Image

Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer

Objective: to evaluate the efficiency (morphological tumor complete regression (mCR), a clinical effect) and safety of the use of new anthracycline-free neoajuvant chemotherapy regimens (paclitaxel + vinorelbine and docetaxel + carboplatin) in combination with trastuzumab in patients with Stage IIIa...

Full description

Saved in:

Bibliographic Details
Main Authors:	K. R. Zeinalova (Author), Ya. V. Vishnevskaya (Author), I. P. Ganshina (Author)
Format:	Book
Published:	ABV-press, 2014-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review
by: I. V. Kolyadina
Published: (2023)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
by: Jiangping Yang, et al.
Published: (2022)

Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04
by: Mei Zhan, et al.
Published: (2023)

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
by: Sadeghi S, et al.
Published: (2014)

Clinical and morphological aspects of neoadjuvant chemotherapy efficacy in patients with aggressive luminal HER2-negative breast cancer
by: D. A. Morozov, et al.
Published: (2022)

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
by: Alessandro D. Santin, et al.
Published: (2017)

Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis
by: Zongyu Li, et al.
Published: (2023)

Trastuzumab deruxtecan versus chemotherapy for patients with HER2-low advanced breast cancer: A US-based cost-effectiveness analysis
by: Youwen Zhu, et al.
Published: (2022)

Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
by: Azadeh Moghaddas, et al.
Published: (2016)

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
by: Steven Simoens, et al.
Published: (2021)

Model‐based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2‐positive advanced or metastatic breast cancer patients
by: Elena M. Tosca, et al.
Published: (2023)

Adverse reactions for the use of the monoclonal trastuzumab antibody in the treatment of patients with HER2 positive breast cancer
by: Iago Dilion Lima Cavalcanti, et al.

Management of inoperable endometrial cancer
by: Supakorn Pitakkarnkul, et al.
Published: (2022)

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
by: Anne Julienne Genuino, et al.
Published: (2019)

Baseline Lymphopenia: A Predictor Of Poor Outcomes In HER2 positive Metastatic Breast Cancer Treated With Trastuzumab
by: Che YQ, et al.
Published: (2019)

An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases
by: A. S. Kolbin, et al.
Published: (2019)

Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report
by: Chen Y, et al.
Published: (2024)

Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer
by: Yiwen You, et al.
Published: (2018)

Ferritin nanoconjugates guide trastuzumab brain delivery to promote an antitumor response in murine HER2 + breast cancer brain metastasis
by: Marta Sevieri, et al.
Published: (2023)

Dual-Targeted Therapy in HER2-Overexpressing Breast Cancer with Trastuzumab and Novel Cholesterol-Based Nioplexes Silencing Mcl-1
by: Supusson Pengnam, et al.
Published: (2023)

Evaluating a targeted Palbociclib-Trastuzumab loaded smart niosome platform for treating HER2 positive breast cancer cells
by: Shaghayegh Saharkhiz, et al.
Published: (2024)

Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine
by: Taha Koray Sahin, et al.
Published: (2024)

Network meta-analysis of treatment regimens for inoperable advanced hepatocellular carcinoma with portal vein invasion
by: Li MF, et al.
Published: (2018)

Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets
by: Philip Lammers, et al.
Published: (2014)

Therapeutic Response Monitoring with <sup>89</sup>Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models
by: Minwoo Kang, et al.
Published: (2022)

Pharmacoeconomic analysis of trastuzumab emtanzine comparing to lapatinib + capecitabine in pa-tients with HER2+ breast cancer and central nervous system metastases
by: A. S. Kolbin, et al.
Published: (2018)

Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers
by: Ratnakar Reddy Kuchukulla, et al.
Published: (2022)

Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
by: Michela Piezzo, et al.
Published: (2021)

Localized co-delivery of collagenase and trastuzumab by thermosensitive hydrogels for enhanced antitumor efficacy in human breast xenograft
by: Anni Pan, et al.
Published: (2018)

Investigating the Combination therapy effect of Trastuzumab and Idarubicin on growth inhibition of HER2-positive breast cancer cells line (SK-BR-3)
by: Moslem Afrakhteh, et al.
Published: (2017)

Health-related quality of life in Her2-positive early breast cancer woman using trastuzumab: A systematic review and meta-analysis
by: Sudewi Mukaromah Khoirunnisa, et al.
Published: (2023)

Response of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case report
by: Peter G. Rose
Published: (2023)

Development and Evaluation of Competitive Inhibitors of Trastuzumab-HER2 Binding to Bypass the Binding-Site Barrier
by: Brandon M. Bordeau, et al.
Published: (2022)

Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression
by: Christina Vasalou, et al.
Published: (2024)

Trastuzumab-Induced Organising Pneumonia in Breast Cancer Patient
by: Sapna Dixit, et al.
Published: (2024)

OUR EXPERIENCE WITH DACARBAZINE IN THE TREATMENT OF PATIENTS WITH INOPERABLE SKIN MELANOMA
by: Deyan Davidov
Published: (2016)

Pharmacoeconomic analysis of using empegfilgrastim for the treatment of early and locally advanced HER2+ breast cancer in the Russian Federation
by: M. V. Zhuravleva, et al.
Published: (2024)

Assessment of survival and cardiotoxicity of adjuvant trastuzumab among HER2 breast cancer patients in an oncology centre in Malaysia / Harissa H Hasbullah ... [et al.]
by: Hasbullah, Harissa H, et al.
Published: (2018)

In Vitro Assessment of <sup>177</sup>Lu-Labeled Trastuzumab-Targeted Mesoporous Carbon@Silica Nanostructure for the Treatment of HER2-Positive Breast Cancer
by: Ayça Tunçel, et al.
Published: (2024)

Combined trastuzumab and radiation therapy for HER2-positive uterine serous carcinoma: A case report
by: SPH Mao, et al.
Published: (2023)